Trial Profile
A Phase II Pilot Study of VELCADE [bortezomib] in Patients With MDS [myelodysplastic syndromes]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2008 New trial record.